The Global Burden of Aortic Stenosis

Thaden, Jeremy J.; Nkomo, Vuyisile T.; Enríquez-Sarano, Maurice

doi:10.1016/j.pcad.2014.02.006

Cited by 225 publications

(160 citation statements)

References 65 publications

Supporting

Mentioning

139

Contrasting

Unclassified

Order By: Relevance

“…CAVD affects approximately 3% of the population aged 75 years or older (Thaden et al 2014), making it an enormous threat to public health in the aging world (d 'Arcy et al 2011). CAVD is a progressive disease (Freeman and Otto 2005).…”

Section: Introductionmentioning

confidence: 99%

Integrated Bioinformatics Analysis Predicts the Key Genes Involved in Aortic Valve Calcification: From Hemodynamic Changes to Extracellular Remodeling

Liu

Luo

Sun

et al. 2017

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

In our aging world, increasing numbers of people are suffering from calcific aortic valve disease (CAVD). In this study, we used integrated bioinformatics analysis to predict several key genes that are involved in the initiation and progression of CAVD. Expression profiles of 15 calcific and 14 normal human aortic valve samples were generated from two gene expression datasets (GSE12644 and GSE51472). Dataset GSE26953 from the human aortic valve fibrosa-derived endothelial cells cultured under laminar or oscillatory shear stress was also evaluated. Related R packages were used to process the data. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed for functional annotation. Hub genes were identified based on the protein-protein interaction network. CAVD-related gene modules were identified by Weighted Gene Co-expression Network Analysis (WGCNA). The predicted key genes were manually reviewed. In our present work, complex connections among mechano-response, oxidative stress, inflammation and extracellular remodeling pathways in the etiology of CAVD were revealed. The key genes, thus identified, encode a transcription factor KLF2 and phospholipid phosphatase 3 (PLPP3) that are involved in mechanoresponses; eNOS involved in oxidative stress; IL-8 involved in inflammation; and collagen triple helix repeat containing 1 (CTHRC1) and secretogranin II (SCG2) involved in extracellular remodeling. These gene products are predicted to play critical roles in CAVD development and progression. The present study provides valuable information for future research and drug development.

show abstract

Section: Introductionmentioning

confidence: 99%

Integrated Bioinformatics Analysis Predicts the Key Genes Involved in Aortic Valve Calcification: From Hemodynamic Changes to Extracellular Remodeling

Liu

Luo

Sun

et al. 2017

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Other important causes include bicuspid valve disease causing 30-40% of cases (8)(9)(10), and rheumatic heart disease, which is more common in developing countries (11).…”

Section: Aortic Stenosis (As) and Its Managementmentioning

confidence: 99%

A review of racial disparities in transcatheter aortic valve replacement (TAVR): accessibility, referrals and implantation

et al. 2018

View full text Add to dashboard Cite

Racial disparities in transcatheter aortic valve replacement (TAVR) implantation results from several factors, including socioeconomic disparities, inherent biases in healthcare provision, fewer referrals to specialists and language barriers in some minority populations. In this review article, we discuss the current data on the racial disparities in TAVR, explore the prevalence of aortic stenosis in different demographics in the United States and we proffer practical solutions to these problems.

show abstract

“…Após o início dos sintomas da doença, geralmente os pacientes com EAo sofrem piora importante de seu prognós-tico, com sobrevida média de dois a três anos (Figura 1) e aumento significativo do risco de morte súbita Thaden et al, 2014). A sobrevida pode ser ainda menor na coexistência de comorbidades cardíacas.…”

Section: Introductionunclassified

Estenose valvular aórtica e o uso de TAVI: revisão narrativa das evidências publicadas e avaliação básica de custos

Follador¹,

Mendoza²,

Gonçalves³

et al. 2018

JBES

View full text Add to dashboard Cite

RESUMOObjetivo: Revisar as evidências clínicas da estenose valvular aórtica em suas dimensões médica e econômica, analisando as alternativas de tratamento cirúrgico em pacientes de alto risco cirúrgico com foco na tecnologia do implante transcateter de válvula aórtica (TAVI). Métodos: Foi elaborada uma revisão narrativa das publicações relacionadas à estenose vascular aórtica e às metodologias de tratamento cirúrgico, assim como a comparação entre a metodologia TAVI e as abordagens convencionais (substituição cirúrgica de válvula aórtica por esternotomia, valvuloplastia por balão intra--aórtico e tratamento farmacológico), abordando ainda dados sobre algumas diferentes marcas e gerações de dispositivos de TAVI oferecidas no mercado brasileiro, avaliando a eficácia, a segurança e o custo de tratamento. Resultados: Em pacientes portadores de estenose aórtica grave sintomá-tica e inoperáveis pela abordagem convencional, o uso do TAVI mostrou ser uma alternativa mais segura, eficaz e econômica em comparação aos tratamentos convencionais. Estudos com robustez metodológica mostram que esse procedimento alcança taxas superiores a 80% de sobrevida em um ano e aproximadamente 30% em cinco anos, mesmo em pacientes de alto risco. No entanto, foram observadas diferenças significativas nos desfechos entre diferentes estudos, que podem ser atribuídas não apenas ao desenho e à amostragem, mas às diferenças entre as diversas opções de gerações e marcas de dispositivos para TAVI disponíveis no mercado. Essas opções diferem principalmente na estrutura, via de inserção e modo de expansão. As válvulas de terceira geração vêm apresentando os melhores resultados em termos de eficácia, segurança e facilidade no procedimento, que resultam em mais benefícios aos pacientes e equilibram os custos de tratamento em médio e longo prazos. Conclusões: Estudos com evidências robustas avaliando desfechos representativos para o tratamento da estenose aórtica grave e sintomática mostram que a tecnologia minimamente invasiva TAVI é eficaz, segura no tratamento de pacientes de alto risco ou inoperáveis, com melhorias significativas nos dispositivos de terceira geração. ABSTRACTObjective: To review the clinical evidences of aortic valve stenosis in its medical and economical settings, reviewing the surgical treatment alternatives in patients at high surgical risk focused on the transcatheter aortic valve implantation (TAVI) technology. Methods: A structured review of the publications related to the disease and to the surgical treatment methodologies was conducted, followed by a search for information about the TAVI methodology, with comparisons between this method and conventional approaches (surgical aortic valve replacement by means of sternotomy, valvuloplasty via intra-aortic balloon and pharmacological treatment) and comparisons between different brands and generations of TAVI devices, evaluating the treatment efficacy, safety and cost.

show abstract

The Global Burden of Aortic Stenosis

Cited by 225 publications

References 65 publications

Integrated Bioinformatics Analysis Predicts the Key Genes Involved in Aortic Valve Calcification: From Hemodynamic Changes to Extracellular Remodeling

Integrated Bioinformatics Analysis Predicts the Key Genes Involved in Aortic Valve Calcification: From Hemodynamic Changes to Extracellular Remodeling

A review of racial disparities in transcatheter aortic valve replacement (TAVR): accessibility, referrals and implantation

Estenose valvular aórtica e o uso de TAVI: revisão narrativa das evidências publicadas e avaliação básica de custos

Contact Info

Product

Resources

About